Semaglutide by quarter
Coverage and results for Semaglutide quarter by quarter. Read the supplier-count column beside the median: a quarter where the compound mix changed is not comparable with the one before it, and the index cannot hold that constant retrospectively.
| Quarter | Batches | Reports | Median purity % | IQR pp | Suppliers | Flagged | What changed in the index |
|---|---|---|---|---|---|---|---|
| 2024-Q1 | 2 | 11 | 98.97 | 0.92 | 2 | 4 | Backfill quarter. Reports assayed earlier were accepted retrospectively where custody could be documented. |
| 2024-Q2 | 8 | 62 | 98.84 | 0.58 | 7 | 11 | First quarter of live submission. |
| 2024-Q3 | 5 | 35 | 98.44 | 1.26 | 5 | 9 | Nordanalyt Laboratories began contributing. |
| 2024-Q4 | 7 | 47 | 99.02 | 0.53 | 7 | 19 | Impurity-fingerprint matching introduced; first shared-bulk links published. |
| 2025-Q1 | 11 | 83 | 98.98 | 1.02 | 7 | 18 | Anomaly rule set expanded from seven rules to eleven. |
| 2025-Q2 | 5 | 17 | 98.94 | 1.11 | 5 | 5 | Gravimetric mass-balance reconciliation became mandatory on new records. |
| 2025-Q3 | 19 | 117 | 98.56 | 1.10 | 13 | 44 | Kestrel Bioanalytical began contributing; gradient-length normalisation introduced. |
| 2025-Q4 | 16 | 104 | 98.85 | 1.50 | 11 | 46 | Provenance classification became a required field. |
| 2026-Q1 | 14 | 106 | 99.03 | 0.79 | 8 | 10 | Rule AX-R12 added. Dataset v2 schema published. |
| 2026-Q2 | 18 | 110 | 98.82 | 0.86 | 10 | 29 | Buyer-sourced sensitivity analysis added to every supplier scorecard. |
| 2026-Q3 | 10 | 76 | 98.98 | 0.81 | 9 | 24 | Quarter in progress. Aggregates for this quarter are provisional. |
Median purity by quarter
Quarters with fewer than two purity records are gaps in the line rather than zeroes. A trend across 11 points, most of them thin, is a shape and not a finding.